Skip to main content
. 2022 Sep 12;127(11):2016–2024. doi: 10.1038/s41416-022-01974-5

Fig. 4. Metagenome panel as a predictive biomarker of overall survival (OS) in patients with EAC.

Fig. 4

a Linear Discriminant Analysis (LDA) showing two significant microbial species in patients with OS ≥ 24 months. b Receiver operating characteristics (ROC) curves showing the prognostic potential of metagenome panel with clinical TNM stage to predict OS ≥ 24 months. c Kaplan–Meier survival curve showing that metagenome panel with clinical TNM stage is able to predict longer OS compared to TNM alone with the hazard ratio (HR) of 6.23 (95% CI, 2.65–14.46, P < 0.001).